- Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Rigel Reports First Quarter 2025 Financial Results and Provides . . .
Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk MDS
- Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . .
"The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO
- Rigel Announces Conference Call and Webcast to Report First Quarter . . .
Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p m Eastern Time (1:30 p m Pacific Time) to discuss the financial results and give an update on the business
- Rigel Reports Third Quarter 2024 Financial Results and Provides . . .
Rigel reported net income of $12 4 million, or $0 71 basic and $0 70 diluted per share, compared to a net loss of $5 7 million, or $0 33 basic and diluted per share, for the same period of 2023
- Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for . . .
SOUTH SAN FRANCISCO, Calif , Oct 24, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO ® (pralsetinib) after
- Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting . . .
Rigel's poster presentations will include data for GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including final data from the Phase 1 2 ARROW study, and REZLIDHIA ® (olutasidenib) for the treatment of relapsed or refractory (R R) mutated
|